Skip to main content
. 2020 Sep 17;26(1):21–29. doi: 10.1634/theoncologist.2020-0165

Figure 1.

Figure 1

Kaplan‐Meier plot of progression‐free survival in 108 patients with grade 1–2 gastroenteropancreatic neuroendocrine tumors on somatostatin analog monotherapy. (A): Probability of progression‐free survival at 6, 12, and 18 months was 90.9% ± 2.9%, 80.0% ± 4.3%, and 60.8% ± 6.3%, respectively (mean ± SEM). (B): There was no significant difference in progression‐free survival between the primary tumor sites (p = .50).